Visualitzant O - Articles científics per títol

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

García-Estévez, Laura; Cortés Castan, Javier; Pérez, Silvia; Calvo, Isabel; Gallegos, Isabel; Moreno-Bueno, Gema (Frontiers Media, 2021-08-13)

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

Blanch, Salvador; Gil Gil, Miguel J.; Arumí De Dios, Míriam; SEGUI PALMER, MIQUEL ANGEL; Atienza, Manuel; AGUIRRE, ELENA (Springer, 2023-10)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Ring, Alistair; Kilburn, Lucy; Pearson, Alex; Moretti, Laura; Afshari-Mehr, Angelica; Wardley, Andrew; Llop Guevara, Alba; Serra, Violeta (American Association for Cancer Research, 2023-12-01)

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Fizazi, Karim; Saad, Fred; Mateo, Joaquin; de Bono, Johann S; Shore, Neal; Sandhu, Shahneen (American Society of Clinical Oncology, 2024-02-10)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Mateo Valderrama, Joaquim; Porta, Nuria; Bianchini, Diletta; McGovern, Ursula; Elliott, Tony; Jones, Robert (Elsevier, 2020-01-01)

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Poveda, Andres; Lheureux, S.; Cibula, David; Weberpals, J.; Oaknin Benzaquen, Ana Mazaltob; Colombo, Nicoletta; Lindemann, Kristina (Elsevier, 2022-03)

Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study

Park, Keunchil; Jӓnne, Pasi A.; Kim, Dong-Wan; Han, Ji-Youn; Wu, Ming-Fang; Lee, Jong-Seok; Felip Font, Enriqueta (Wiley, 2021-05-01)

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

de la Fuente, Macarena; Colman, Howard; Rosenthal, Mark; Van Tine, Brian; Levacic, Danijela; Walbert, Tobias; Vieito Villar, Maria (Oxford University Press, 2023-01)

Oncological care organisation during COVID-19 outbreak

Onesti, Concetta Elisa; Generali, Daniele; Peeters, Marc; Zaman, Khalil; Wildiers, Hans; Cortés Castan, Javier; Rugo, Hope (BMJ, 2020-08-26)

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Ricordel, Charles; Isambert, Nicolas; Herrera-Juárez, Mercedes ; Martinez Marti, Alexandre; Ponce Aix, Santiago; cedres, susana; Viteri, Santiago; NAVARRO, ALEJANDRO; Serres-Créixams, Xavier (BMJ, 2023-09)

Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers

Cohen-Adad, Julien; Alonso-Ortiz, Eva; Abramovic, Mihael; Arneitz, Carina; Atcheson, Nicole; Barlow, Laura; Pareto Onghena, Deborah; Rovira Cañellas, Alex; Grussu, Francesco (Nature Research, 2021-08-16)

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

McDermott, David F.; Lee, Jae-Lyun; Ziobro, Marek; Suárez Rodríguez, Cristina; Langiewicz, Przemyslaw; Matveev, Vsevolod Borisovich (American Society of Clinical Oncology, 2021-03-20)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Adamo, Barbara; Pascual, Tomás; Vidal, Maria; Pérez Fidalgo, José A; Gómez Pardo, Patricia; Paré, Laia; Bellet Ezquerra, Meritxell (Springer Nature, 2019-09-18)

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Salmanton‑García, Jon; Marchesi, Francesco; Seval, Guldane Cengiz; Jimenez Balarezo, Moraima; Busca, Alessandro; van Doesum, Jaap; Farina, Francesca (Frontiers Media, 2023-02-24)

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Blennow, Ola; Salmanton‑García, Jon; Nowak, Piotr; Lopez-Garcia, Alberto; Jimenez Balarezo, Moraima; Cabirta Touzon, Alba; van Doesum, Jaap; Itri, Federico (Wiley, 2022-08)

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

Ernst, Matthew; Navani, Vishal; Wells, Connor; Donskov, Frede; Basappa, Naveen; Labaki, Chris; Suárez, Cristina (Elsevier, 2023-07)

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Marchetti, Monia; Salmanton‑García, Jon; Verga, Luisa; Ráčil, Zdeněk; Jimenez Balarezo, Moraima; Cabirta Touzon, Alba; Itri, Federico; El-Ashwah, Shaimaa (SAGE Publications, 2023)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Serna-Blasco, Roberto; Garcia‑Campelo, Rosario; Casal Rubio, Joaquín; Martínez Marti, Alexandre; Insa, Amelia; Provencio, Mariano; Nadal, Ernest (American Society of Clinical Oncology, 2022-09-01)

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Michels, Sebastian; Vasyliv, I.; Stratmann, Jan Alexander; Frank, Julia; Adams, Alexandra M.; Massuti, Bartomeu; FELIP, ENRIQUETA (Elsevier, 2024-02)

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Geyer, C. E. Jr; Garber, J. E.; Gelber, R. D.; Yothers, Greg; Taboada, M.; Ross, L.; Balmaña Gelpí, Judith (Elsevier, 2022-12)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Oncological care organisation during COVID-19 outbreak

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status ﻿

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS) ﻿

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010) ﻿

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial ﻿

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial ﻿

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis ﻿

Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study ﻿

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial ﻿

Oncological care organisation during COVID-19 outbreak ﻿

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment ﻿

Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers ﻿

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma ﻿

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial ﻿

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry ﻿

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report ﻿

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma ﻿

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry ﻿

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial) ﻿

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial ﻿

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Oncological care organisation during COVID-19 outbreak

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer